A Phase 3 interventional study of Saxagliptin and Dapagliflozin in Diabetes, sponsored by AstraZeneca. Completed at 84 sites in 10 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 9th registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 444 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 66 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 27th largest by enrollment of the 91 interventional ones that give a count, is one of 6 that started in 2015, is one of 49 in phase 3, and was the 106th registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the addition of glimepiride to metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on Metformin Alone. We will compare the change from baseline in HbA1c achieved with saxagliptin, in co-administration with dapagliflozin, added to current background therapy with metformin compared to glimepiride added to current background therapy with metformin ≥1500 mg at Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
Drug: Saxagliptin · Drug: Dapagliflozin · Other: Placebo
Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
Drug: Glimepiride · Other: Placebo
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
Time frame: Baseline and Week 52
Change From Baseline in Total Body Weight at Week 52
To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
Time frame: Baseline and Week 52
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52
Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.
Time frame: At Week 52
Change From Baseline in Systolic Blood Pressure (SBP) at Week 52
To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
Time frame: Baseline and Week 52
Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period.
Time frame: Up to Week 52
Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period.
Time frame: Up to Week 156
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156
Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.
Time frame: At Week 156
Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model.
Time frame: Up to Week 156
A total of 444 subjects were randomized in this international, multi-center study which was conducted at 88 centers in 10 countries between 14 Aug 2015 and 18 September 2019.
| Milestone | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Started | 227 | 217 |
| Recevied treatment | 227 | 216 |
| Completed | 210 | 194 |
| Not completed | 17 | 23 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Withdrawal by subject | 9 | 9 |
| Withdrew: Subject request to discontinue treatment | 1 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Worsening of liver function | 0 | 1 |
| Withdrew: Subject moved out of state | 0 | 1 |
| Milestone | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Started | 196 | 186 |
| Received treatment | 196 | 183 |
| Completed | 174 | 164 |
| Not completed | 22 | 22 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Other | 4 | 4 |
| Withdrew: Subject decision | 2 | 4 |
| Withdrew: Withdrawal by subject | 8 | 2 |
To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
| % HbA1c | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52 | -1.35 (-1.49 to -1.22) | -0.98 (-1.12 to -0.84) |
To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
| kilogram (kg) | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Change From Baseline in Total Body Weight at Week 52 | -3.11 (-3.65 to -2.57) | 0.95 (0.38 to 1.51) |
Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.
| Percentage of subjects | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52 | 44.3 (37.45 to 51.32) | 34.3 (27.87 to 41.33) |
To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.
| mmHg | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 52 | -2.6 (-4.4 to -0.8) | 1.0 (-0.9 to 2.9) |
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period.
| Percentage of Subjects | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period | 1.3 | 8.8 |
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period.
| Percentage of Subjects | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period. | 37.0 | 55.6 |
Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.
| Percentage of Subjects | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156 | 21.4 (16.30 to 27.64) | 11.7 (8.03 to 16.82) |
Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model.
| Weeks | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period. | NA (NA to NA) | 92.3 (73.0 to 105.7) |
Collected over All adverse events (AEs), including serious adverse events (SAEs), were collected on or after the date of first dose of short-term study medication and up to and including 4 days (other AEs) or 30 days (SAEs) after last dose. Up to a total of 160 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 10mg and Saxagliptin 5mg | 1/227 (0.4%) | 29/227 (12.8%) | 99/227 (43.6%) |
| Titrated Glimepiride | 3/216 (1.4%) | 24/216 (11.1%) | 106/216 (49.1%) |
| Event | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| PneumoniaInfections and infestations | 1/227 | 2/216 |
| Ischaemic strokeNervous system disorders | 0/227 | 2/216 |
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/227 | 2/216 |
| Vertebrobasilar insufficiencyNervous system disorders | 2/227 | 0/216 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/227 | 0/216 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/227 | 0/216 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 2/227 | 0/216 |
| Vertigo positionalEar and labyrinth disorders | 0/227 | 1/216 |
| Obstructive pancreatitisGastrointestinal disorders | 0/227 | 1/216 |
| Non-cardiac chest painGeneral disorders | 0/227 | 1/216 |
| Event | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride |
|---|---|---|
| Urinary tract infectionInfections and infestations | 31/227 | 21/216 |
| Upper respiratory tract infectionInfections and infestations | 23/227 | 21/216 |
| NasopharyngitisInfections and infestations | 14/227 | 19/216 |
| HypertensionVascular disorders | 7/227 | 18/216 |
| HeadacheNervous system disorders | 18/227 | 16/216 |
| BronchitisInfections and infestations | 11/227 | 17/216 |
| DyslipidaemiaMetabolism and nutrition disorders | 2/227 | 13/216 |
| InfluenzaInfections and infestations | 9/227 | 12/216 |
| PharyngitisInfections and infestations | 6/227 | 12/216 |
| DiarrhoeaGastrointestinal disorders | 10/227 | 12/216 |
Baseline characteristics are presented for the randomized subjects data set which included all randomized subjects who received at least 1 dose of study medication during the double-blind treatment period.
| Age, Continuous(Years) | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride | Total |
|---|---|---|---|
| Mean | 56.1 ± 10.11 | 56.1 ± 9.23 | 56.1 ± 9.68 |
| Sex: Female, Male(Participants) | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride | Total |
|---|---|---|---|
| Female | 110 | 115 | 225 |
| Male | 117 | 101 | 218 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin 10mg and Saxagliptin 5mg | Titrated Glimepiride | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 11 | 10 | 21 |
| Black Or African American | 4 | 5 | 9 |
| Native Hawaiian Or Other Pacific Islander | 0 | 1 | 1 |
| Other | 6 | 4 | 10 |
| White | 206 | 196 | 402 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2015 to primary completion in Aug 2017, 24 months.
Results were first posted in Oct 2018, 1 year 1 month after primary completion.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 24 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Dapagliflozin · Glimepiride